DTIL
Precision BioSciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The constructive case is that DTIL still has two wholly owned clinical-stage in vivo gene-editing programs moving forward at once, with PBGENE-HBV producing ongoing cohort progress and PBGENE-DMD now enrolling, while management says existing cash supports multiple readouts through 2028.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -11.7.
What can break
Clinical data remain early and event-driven; unfavorable safety, efficacy, or durability signals in PBGENE-HBV or PBGENE-DMD could reset the equity sharply.
Momentum
80
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $3.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $29.60
Why
Momentum80 · Δ7d -11.7
Value41 · Δ7d +0.1
Sentiment61 · Δ7d +13.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
80
26% active weight
Current posture
7d trendSoftening
Δ7d
-11.7
Δ21d
+38.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
61
34% active weight
Current posture
7d trendImproving
Δ7d
+13.1
Δ21d
+3.8
Why this grade
Composite grade B. Momentum 80.0 / Value 41.1 / Sentiment 61.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$196.61M
Beta
1.31
Shares Out
25.8M
P/E (TTM) · Derived
-2.1
P/S (TTM)
133.84
P/FCF (TTM) · Derived
-1.93
Rev YoY
+37272.4%
EPS YoY
-66.2%
Gross Margin
+94.0%
Op Margin
-12822.6%
Net Debt
-$86.78M
Current Ratio
14.02
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology